Maze Therapeutics, Inc. Common Stock (MAZE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has a cash flow conversion efficiency ratio of -0.114x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.11 Million) by net assets ($341.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Maze Therapeutics, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Maze Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Maze Therapeutics, Inc. Common Stock to evaluate the quality of earnings relative to operating cash generation.
Maze Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harbin Electric
F:HP6H
|
0.039x |
|
SPG Co. Ltd
KQ:058610
|
0.025x |
|
Privi Speciality Chemicals Limited
NSE:PRIVISCL
|
0.163x |
|
Serena Energia S.A.
SA:SRNA3
|
-0.007x |
|
Xiamen Solex High-Tech Industries Co Ltd
SHG:603992
|
0.021x |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
-0.028x |
|
Shanghai Pret Composites
SHE:002324
|
0.095x |
|
Silicon2 Co. Ltd.
KQ:257720
|
0.069x |
Annual Cash Flow Conversion Efficiency for Maze Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Maze Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see MAZE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $354.97 Million | $-111.94 Million | -0.315x | -181.75% |
| 2024-12-31 | $196.90 Million | $75.95 Million | 0.386x | +104.47% |
| 2023-12-31 | $10.05 Million | $-86.83 Million | -8.636x | -783.11% |
| 2022-12-31 | $101.44 Million | $-99.20 Million | -0.978x | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral s… Read more